High-yield production of major T-cell ESAT6-CFP10 fusion antigen of M. tuberculosis complex employing codon-optimized synthetic gene

Gutiérrez-Ortega, Abel; Moreno, Débora Antunes Neto; Ferrari, Susanna; Espinosa‐Andrews, Hugo; Ortíz, E.P.; Milián-Suazo, Feliciano; Álvarez, Ángel H.

doi:10.1016/j.ijbiomac.2020.12.179

Cited by 4 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antigens can alert immune cells and precipitate an immunological reaction [323]. If these antigens can be engineered in such a way that they target proteins of M. tuberculosis, such as ESAT-6, CFP-10, and TB 7.7, these antigens can be used effectively against TB bacilli [324]. Accordingly, amino acid polymers that self-assembled to form a hollow core-shaped nanobead were administered to TB patients and produced different cytokines, including IFN-γ, INF-α, IL-2, CCL3, and CCL11 [325].…”

Section: Immunotherapymentioning

confidence: 99%

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Nair,

Greeny,

Nandan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance. Graphical Abstract

show abstract

Section: Immunotherapymentioning

confidence: 99%

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Nair,

Greeny,

Nandan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…The multi-epitope constructs enable a higher immunogenic density and diminish the cross-reaction risk of whole bacteria antigen, which is common in leprosy diagnosis [27]. Diseases such as hepatitis B [23], Chagas disease [28], cryptococcosis [25], leishmaniosis [29,30], tuberculosis [31], and toxocariasis [32] already have great results with recombinant multi-epitope proteins in their diagnosis.…”

Section: Introductionmentioning

confidence: 99%

In silico designing of a recombinant multi-epitope antigen for leprosy diagnosis

Lemes

Rodrigues

Jaiswal

et al. 2022

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Leprosy is caused by Mycobacterium leprae and Mycobacterium lepromatosis. Most of the affected population lives in low-income countries and may take up to 10 years to show any clinical signs, which is how physicians diagnose it. However, due to progressive cell damage, early diagnosis is very important. The best way to confirm leprosy is through bacilloscopic, which only confirms the diagnosis and has low accuracy or PCR, that requires specialized operators and is expensive. Since the bacteria are fastidious and do not grow in any culture media, therefore, diagnosing leprosy in the lab is still a challenge. In this concern, a recombinant multi-epitope protein can be a beneficial strategy in the management of the diagnosis, as diverse immunogenic epitopes are precisely selected to detect specific antibodies. Therefore, the purposes of the present study were to select immunogenic epitopes from different relevant proteins, with immunogenic properties, and then to construct a recombinant multi-epitope protein that accuses the presence of the antibodies in the early stages of the disease, making it more than appropriate to be applied as a diagnostic tool. Results We selected 22 common proteins from both species and, using bioinformatics tools, predicted B and T cell epitopes. After multiple filtering and analyzing, we ended up with 29 epitopes {MHC-I (total 18) and MHC-II (total 11)} from 10 proteins, which were then merged into one construct. Its secondary and tertiary structures were also predicted and refined to comprise the amino acid residues in the best conformation possible. The multi-epitope protein construct was stable, non-host homologous, non-allergic, non-toxic, and elicit humoral and cellular responses. It has conformational B cell epitopes and potential to elicit IFN-γ, IL-4, and IL-10 secretion. Conclusions This novel recombinant multi-epitope protein constructed using the common epitopes from M. leprae and M. lepromatosis has a huge immunological potential, is stable, and can be lyophilized to be used in ELISA plates or even in biosensors, which are user-friendly diagnosis tools, facilitating translation into human sample tests.

show abstract

Codon usage divergence of important functional genes in Mycobacterium tuberculosis

Zhang

Xue

2022

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

High-yield production of major T-cell ESAT6-CFP10 fusion antigen of M. tuberculosis complex employing codon-optimized synthetic gene

Cited by 4 publications

References 48 publications

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

In silico designing of a recombinant multi-epitope antigen for leprosy diagnosis

Codon usage divergence of important functional genes in Mycobacterium tuberculosis

Contact Info

Product

Resources

About